Sequential dosing with zoledronate following OPG:Fc treatment protects against rebound bone loss

Sequential dosing with zoledronate following OPG:Fc treatment protects against rebound bone loss

Bibliographic Details
Main Authors:	Jad Zamerli, Sindhu Mohanty, Ya Xiao, Albert Kim, Jacqueline Center, Christian Girgis, Peter Croucher, Michelle Mcdonald
Format:	Article
Language:	English
Published:	Elsevier 2021-04-01
Series:	Bone Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352187221002710

Similar Items

HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
by: Rasmus Offersen, et al.
Published: (2020-12-01)

RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study
by: Laura Mercatali, et al.
Published: (2013-05-01)

To rebound or not to rebound
by: Bethany A Stahl, et al.
Published: (2017-10-01)

Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy
by: Sébastien S. Dufresne, et al.
Published: (2018-04-01)

Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture
by: Ying Wu, et al.
Published: (2013-01-01)

Single Dose Therapy of Zoledronic Acid for the Treatment of Transient Osteoporosis of Hip
by: Sanjay Agarwala, et al.
Published: (2019-06-01)

Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
by: Elie Akoury, et al.
Published: (2019-02-01)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer
by: Xinmin Zhao, et al.
Published: (2015-09-01)

Testing the efficacy of a human full-length OPG-Fc analog in a severe model of cardiotoxin-induced skeletal muscle injury and repair
by: Zineb Bouredji, et al.
Published: (2021-06-01)

Effect of Systemic Zoledronic Acid Dosing Regimens on Bone Regeneration in Osteoporotic Rats
by: Marwa Y. Shaheen, et al.
Published: (2021-02-01)

Collapsing Focal Segmental Glomerulosclerosis Resulting from a Single Dose of Zoledronate
by: Javier A. Neyra, et al.
Published: (2014-10-01)

Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial
Published: (2012-09-01)

C Spine Fracture on OPG
by: Kedarnath N.S., et al.
Published: (2013-08-01)

Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis
by: Elie Akoury, et al.
Published: (2019-08-01)

Biology of the RANKL-RANK-OPG System
by: Yongwon eChoi, et al.
Published: (2014-10-01)

High-Dose Diosgenin Reduces Bone Loss in Ovariectomized Rats via Attenuation of the RANKL/OPG Ratio
by: Zhiguo Zhang, et al.
Published: (2014-09-01)

Dose-Dependent Effects of Zoledronic Acid on Human Periodontal Ligament Stem Cells: An Pilot Study
by: Anna Di Vito, et al.
Published: (2020-10-01)

Roadmap to Rebound: How to Address Rebound Effects from Resource Efficiency Policy
by: David Font Vivanco, et al.
Published: (2018-06-01)

Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats
by: T. Shimizu, et al.
Published: (2017-12-01)

360 Degree Panorama Synthesis From Sequential Views Based on Improved FC-Densenets
by: Dandan Zhu, et al.
Published: (2019-01-01)

RANK/RANKL/OPG system in the intervertebral disc
by: Norihiko Takegami, et al.
Published: (2017-06-01)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
by: Lili Zhang, et al.
Published: (2016-11-01)

The participation of RANK, RANKL and OPG in tumor osteolysis
by: Marcin Stanisławowski, et al.
Published: (2009-05-01)

Salivary level of RANKL and OPG in chronic periodontitis
by: Batool H Al-Ghurabi, et al.
Published: (2015-03-01)

Combination therapy with low-dose teriparatide and zoledronate contributes to fracture healing on rat femoral fracture model
by: Yuta Tsubouchi, et al.
Published: (2018-10-01)

Long-term sequential receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) expression in lipopolysaccharide-induced rat periapical lesions
by: Fu-Hsiung Chuang, et al.
Published: (2013)

ZOLEDRONATE-ASSOCIATED RECURRENCE OF OSTEONECROSIS OF JAWS
by: Rosen Tsolov, et al.
Published: (2020-10-01)

The anti-tumour effects of zoledronic acid
by: Jamal Zekri, et al.
Published: (2014-03-01)

Inhibition of osteoblast activity by zoledronic acid
by: Fernanda Gonçalves Basso, et al.
Published: (2013-10-01)

Targeting tumour-associated angiogenesis with zoledronate
by: Metcalf, Stephen
Published: (2012)

Zoledronic acid plus methylprednisolone zoledronic acid or placebo in symptomatic knee osteoarthritis: a randomized controlled trial
by: Guoqi Cai, et al.
Published: (2019-10-01)

Measuring Impact Rebound with Photography
by: Sumali Hartono
Published: (2010-06-01)

Counterintuitive publicity and the rebound effect
by: Francisco Leite, et al.
Published: (2007-10-01)

Rebound predictions of mechanical collisions
by: Lai, Liang-Ju
Published: (2012)

Rebound predictions for elastic collisions
by: Liu, Pao-pao
Published: (2013)

Sustainability politics : the consequences of rebounds
by: Alcott, Blake
Published: (2013)

Rebound and Spillovers: Prosumers in Transition
by: Elisabeth Dütschke, et al.
Published: (2021-04-01)

Alveolar socket healing in 5-lipoxygenase knockout aged female mice treated or not with high dose of zoledronic acid
by: Ramez H. Mahmoud, et al.
Published: (2021-10-01)

Myb deficiency impacts Rank-Rankl-Opg system
by: Veronika Oralova, et al.
Published: (2020-10-01)

Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
by: Jie Ming, et al.
Published: (2020-08-01)